Abstract
IntroductionThe TYSABRI Observational Program (TOP) is an ongoing observational study of natalizumab treatment in relapsing-remitting multiple sclerosis (RRMS) patients. Country-specific data on relapse and disability outcomes, alongside global data, can...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have